Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Drug Portfolio

DRUG(2)

CEOP chemotherapy regimen for 6 cycles

1 trial

phase_2

shandong-provincial-hospital

CEOP/IVE/GDP chemotherapy regimen

1 trial

phase_2

shandong-provincial-hospital

2 unique interventions1 categories

Analytics

Trial Phases

Phase 21

Trial Status

Other1

Role Distribution

Principal Investigator1

PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT02533700Phase 2Unknown

CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL

ALK-negative Anaplastic Large Cell LymphomaAngioimmunoblastic T Cell LymphomaEnteropathy Associated T Cell Lymphoma+3 more

PrincipalinvestigatorStart date: 2015-09-01

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

ALK-negative Anaplastic Large Cell Lymphoma1 Angioimmunoblastic T Cell Lymphoma1 Enteropathy-Associated T-Cell Lymphoma1 Hepatosplenic T-cell Lymphoma1 Peripheral T-Cell Lymphoma, Not Otherwise Specified1 Subcutaneous Panniculitis Like T Cell Lymphoma1

Affiliations

Shanghai Province Hopsital

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Alex F Herrera

City of Hope Medical Center

9 trials

Shared therapeutic areas:

Enteropathy-Associated T-Cell LymphomaHepatosplenic T-cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise Specified

Similarity Score15%

Thomas E. Witzig, MD

Mayo Clinic

12 trials

Shared therapeutic areas:

Enteropathy-Associated T-Cell LymphomaHepatosplenic T-cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise Specified

Similarity Score15%

Thomas Witzig

Mayo Clinic

4 trials

Shared therapeutic areas:

Enteropathy-Associated T-Cell LymphomaHepatosplenic T-cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise Specified

Similarity Score15%

Steven Horwitz, MD

Memorial Sloan Kettering Cancer Center

7 trials

Shared therapeutic areas:

Enteropathy-Associated T-Cell LymphomaHepatosplenic T-cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise Specified

Similarity Score15%

Geoffrey Uy, M.D.

Washington University School of Medicine

5 trials

Shared therapeutic areas:

Enteropathy-Associated T-Cell LymphomaHepatosplenic T-cell Lymphoma

Similarity Score10%

Yeow Tee Goh, MBBS MMed

Singapore General Hospital

2 trials

Shared therapeutic areas:

Hepatosplenic T-cell LymphomaPeripheral T-Cell Lymphoma, Not Otherwise Specified

Similarity Score10%

Deepa Jagadeesh, MD, MPH

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

3 trials

Shared therapeutic areas:

Enteropathy-Associated T-Cell LymphomaHepatosplenic T-cell Lymphoma

Similarity Score10%

Kevin C Conlon, M.D.

National Cancer Institute (NCI)

10 trials

Shared therapeutic areas:

Enteropathy-Associated T-Cell LymphomaHepatosplenic T-cell Lymphoma

Similarity Score10%

Jonathan Moreira, MD

Northwestern University

2 trials

Shared therapeutic areas:

Hepatosplenic T-cell Lymphoma

Similarity Score5%

George Chen

Roswell Park Cancer Institute

2 trials

Shared therapeutic areas:

Hepatosplenic T-cell Lymphoma

Similarity Score5%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT02533700Phase 2PrincipalInvestigator

CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL

ALK-negative Anaplastic Large Cell LymphomaAngioimmunoblastic T Cell LymphomaEnteropathy Associated T Cell Lymphoma+3 more

Unknown

All 1 trials loaded